ST香雪：公司重视TAEST16001的临床价值与市场潜力，正全力推进确证性临床试验筹备阶段的工作

Core Viewpoint - The company is under scrutiny from investors regarding the status of its clinical trial for TAEST16001, with concerns about transparency in communication and adherence to disclosure rules [1] Group 1: Company Response - The company emphasizes the importance of TAEST16001's clinical value and market potential, stating that it is fully committed to advancing the preparatory phase of the confirmatory clinical trial [1] - The company has previously disclosed progress in the new drug development phase and will continue to provide updates based on clinical developments in accordance with information disclosure regulations [1]